Review Article | Published:

Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells

Nature Medicine volume 19, pages 859868 (2013) | Download Citation

Abstract

Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections account for 57% of cases of liver cirrhosis and 78% of cases of primary liver cancer worldwide and cause a million deaths per year. Although HBV and HCV differ in their genome structures, replication strategies and life cycles, they have common features, including their noncytopathic nature and their capacity to induce chronic liver disease, which is thought to be immune mediated. However, the rate of disease progression from chronic hepatitis to cirrhosis varies greatly among infected individuals, and the factors that regulate it are largely unknown. This review summarizes our current understanding of the roles of antigen-specific and nonspecific immune cells in the pathogenesis of chronic hepatitis B and C and discusses recent findings that identify natural killer cells as regulators of T cell function and liver inflammation.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. 1, 23–61 (2006).

  2. 2.

    Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J. Clin. Invest. 119, 1745–1754 (2009).

  3. 3.

    & Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5, 215–229 (2005).

  4. 4.

    et al. CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Virol. 77, 68–76 (2003).

  5. 5.

    et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 197, 1645–1655 (2003).

  6. 6.

    et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 81, 4215–4225 (2007).

  7. 7.

    et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 53, 1494–1503 (2011).

  8. 8.

    et al. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 45, 588–601 (2007).

  9. 9.

    et al. Impaired effector function of hepatitis C virus–specific CD8+ T cells in chronic hepatitis C virus infection. J. Immunol. 169, 3447–3458 (2002).

  10. 10.

    et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J. Virol. 81, 2545–2553 (2007).

  11. 11.

    et al. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J. Clin. Invest. 120, 4546–4557 (2010).

  12. 12.

    et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 369, 407–410 (1994).

  13. 13.

    , , & Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection. J. Clin. Invest. 96, 1527–1534 (1995).

  14. 14.

    et al. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J. Clin. Invest. 100, 2376–2385 (1997).

  15. 15.

    et al. Human leukocyte antigen–associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. Hepatology 46, 339–349 (2007).

  16. 16.

    et al. Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire. J. Immunol. 181, 6435–6446 (2008).

  17. 17.

    et al. Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection. Gastroenterology 117, 1386–1396 (1999).

  18. 18.

    et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191, 1499–1512 (2000).

  19. 19.

    , , & The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 2, 1104–1108 (1996).

  20. 20.

    et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 302, 659–662 (2003).

  21. 21.

    et al. Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J. Clin. Invest. 119, 376–386 (2009).

  22. 22.

    et al. Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology 140, 686–696.e1 (2011).

  23. 23.

    et al. Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection. Gut 60, 1563–1571 (2011).

  24. 24.

    et al. Maintenance of HCV-specific T-cell responses in antibody-deficient patients a decade after early therapy. Blood 107, 4570–4571 (2006).

  25. 25.

    et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat. Med. 6, 578–582 (2000).

  26. 26.

    et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132, 667–678 (2007).

  27. 27.

    et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41, 771–778 (2005).

  28. 28.

    et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J. Immunol. 177, 739–747 (2006).

  29. 29.

    et al. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 38, 1437–1448 (2003).

  30. 30.

    et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J. Exp. Med. 205, 2111–2124 (2008).

  31. 31.

    et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage. J. Exp. Med. 204, 667–680 (2007).

  32. 32.

    et al. Transient CD86 expression on hepatitis C virus-specific CD8+ T cells in acute infection is linked to sufficient IL-2 signaling. J. Immunol. 184, 2410–2422 (2010).

  33. 33.

    et al. IL-10–producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J. Immunol. 189, 3925–3935 (2012).

  34. 34.

    et al. Hepatic expansion of a virus-specific regulatory CD8+ T cell population in chronic hepatitis C virus infection. J. Clin. Invest. 113, 963–972 (2004).

  35. 35.

    et al. Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor β that can suppress HCV-specific T-cell responses. J. Virol. 81, 5882–5892 (2007).

  36. 36.

    et al. Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations. Hepatology 54, 1157–1166 (2011).

  37. 37.

    , , , & Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion. J. Immunol. 182, 6697–6708 (2009).

  38. 38.

    & High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. USA 106, 8623–8628 (2009).

  39. 39.

    et al. High-programmed death-1 levels on hepatitis C virus–specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J. Immunol. 181, 8215–8225 (2008).

  40. 40.

    , & Human T cell response to the surface antigen of hepatitis B virus (HBsAg). Endosomal and nonendosomal processing pathways are accessible to both endogenous and exogenous antigen. J. Exp. Med. 168, 293–306 (1988).

  41. 41.

    et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 143, 963–973 e9 (2012).

  42. 42.

    et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog. 6, e1000947 (2010).

  43. 43.

    et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog. 5, e1000313 (2009).

  44. 44.

    et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682–687 (2006).

  45. 45.

    et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J. Virol. 83, 9122–9130 (2009).

  46. 46.

    et al. The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology 52, 1934–1947 (2010).

  47. 47.

    et al. Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ T cells. PLoS Pathog. 7, e1002045 (2011).

  48. 48.

    et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10, 29–37 (2009).

  49. 49.

    et al. PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosis. J. Hepatol. 45, 520–528 (2006).

  50. 50.

    , , , & PD-1 inhibits antiviral immunity at the effector phase in the liver. J. Exp. Med. 198, 39–50 (2003).

  51. 51.

    et al. In vivo immune modulatory activity of hepatic stellate cells in mice. Hepatology 44, 1171–1181 (2006).

  52. 52.

    , & Oscillating CD8+ T cell effector functions after antigen recognition in the liver. Immunity 23, 53–63 (2005).

  53. 53.

    et al. Intrahepatic expression of programmed death-1 and its ligands in patients with HBV-related acute-on-chronic liver failure. Inflammation 36, 110–120 (2013).

  54. 54.

    T cell exhaustion. Nat. Immunol. 12, 492–499 (2011).

  55. 55.

    , , & Role of Bim in regulating CD8+ T-cell responses during chronic viral infection. J. Virol. 80, 8627–8638 (2006).

  56. 56.

    et al. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J. Clin. Invest. 118, 1835–1845 (2008).

  57. 57.

    et al. Persistent hepatitis C virus (HCV) infection impairs HCV-specific cytotoxic T cell reactivity through Mcl-1/Bim imbalance due to CD127 down-regulation. J. Viral Hepat. 20, 85–94 (2013).

  58. 58.

    et al. Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV. Gastroenterology 143, 1576–1585e.4 (2012).

  59. 59.

    et al. Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 134, 1927–1937, 1937.e1–2 (2008).

  60. 60.

    et al. Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. Blood 107, 4424–4432 (2006).

  61. 61.

    et al. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog. 6, e1001227 (2010).

  62. 62.

    et al. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-α and plasmacytoid dendritic cell loss in chronic HCV infection. J. Immunol. 177, 6758–6768 (2006).

  63. 63.

    et al. TLR-dependent cross talk between human Kupffer cells and NK cells. J. Exp. Med. 205, 233–244 (2008).

  64. 64.

    et al. IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences. Blood 102, 4487–4492 (2003).

  65. 65.

    , , & Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J. Immunol. 160, 3188–3193 (1998).

  66. 66.

    , & Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C. Virulence 3, 610–620 (2012).

  67. 67.

    et al. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology 42, 104–112 (2005).

  68. 68.

    et al. Transmission of clonal hepatitis C virus genomes reveals the dominant but transitory role of CD8+ T cells in early viral evolution. J. Virol. 85, 11833–11845 (2011).

  69. 69.

    et al. Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proc. Natl. Acad. Sci. USA 108, 21182–21187 (2011).

  70. 70.

    , , , & Role of antigen persistence and dose for CD4+ T-cell exhaustion and recovery. Proc. Natl. Acad. Sci. USA 107, 20453–20458 (2010).

  71. 71.

    et al. Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology 51, 378–387 (2010).

  72. 72.

    et al. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J. Hepatol. 28, 84–90 (1998).

  73. 73.

    et al. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J. Hepatol. 51, 458–467 (2009).

  74. 74.

    et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 137, 1151–1160, 1160.e1–7 (2009).

  75. 75.

    et al. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology 43, 573–580 (2006).

  76. 76.

    et al. The trafficking of natural killer cells. Immunol. Rev. 220, 169–182 (2007).

  77. 77.

    et al. Critical role for the chemokine receptor CXCR6 in NK cell–mediated antigen-specific memory of haptens and viruses. Nat. Immunol. 11, 1127–1135 (2010).

  78. 78.

    , , & T cell– and B cell–independent adaptive immunity mediated by natural killer cells. Nat. Immunol. 7, 507–516 (2006).

  79. 79.

    et al. Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut 55, 869–877 (2006).

  80. 80.

    et al. Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection. Hepatology 56, 841–849 (2012).

  81. 81.

    et al. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-α–dependent manner. Gastroenterology 138, 325–335.e1–2 (2010).

  82. 82.

    et al. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur. J. Immunol. 37, 445–455 (2007).

  83. 83.

    , , , & Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J. Hepatol. 54, 209–218 (2011).

  84. 84.

    et al. Plasmacytoid dendritic cells sense hepatitis C virus–infected cells, produce interferon, and inhibit infection. Proc. Natl. Acad. Sci. USA 107, 7431–7436 (2010).

  85. 85.

    et al. innate immune tolerance and the role of Kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology 144, 402–413.e12 (2012).

  86. 86.

    et al. Interferon α/β–mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox. Nat. Immunol. 1, 70–76 (2000).

  87. 87.

    et al. High basal STAT4 balanced by STAT1 induction to control type 1 interferon effects in natural killer cells. J. Exp. Med. 204, 2383–2396 (2007).

  88. 88.

    et al. Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology 55, 39–48 (2012).

  89. 89.

    et al. Altered interferon-α-signaling in natural killer cells from patients with chronic hepatitis C virus infection. J. Hepatol. 53, 424–430 (2010).

  90. 90.

    et al. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 141, 1231–1239, 1239.e1–2 (2011).

  91. 91.

    et al. Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment. Eur. J. Immunol. 41, 2905–2914 (2011).

  92. 92.

    et al. Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. J. Hepatol. published online, (14 March 2013).

  93. 93.

    et al. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 44, 352–359 (2006).

  94. 94.

    et al. Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology 142, 1122–1131.e1 (2012).

  95. 95.

    et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl. Acad. Sci. USA 105, 7034–7039 (2008).

  96. 96.

    et al. Genetic variation in IL28B predicts hepatitis C treatment–induced viral clearance. Nature 461, 399–401 (2009).

  97. 97.

    et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41, 1105–1109 (2009).

  98. 98.

    et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat. Genet. 41, 1100–1104 (2009).

  99. 99.

    et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45, 164–171 (2013).

  100. 100.

    et al. Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C. Hepatology 54, 1559–1569 (2011).

  101. 101.

    et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J. Exp. Med. 178, 1541–1554 (1993).

  102. 102.

    , & Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J. Virol. 71, 3236–3243 (1997).

  103. 103.

    , , & Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice. J. Virol. 73, 474–481 (1999).

  104. 104.

    , & Characterization of nuclear RNases that cleave hepatitis B virus RNA near the La protein binding site. J. Virol. 75, 6874–6883 (2001).

  105. 105.

    et al. Analysis of CD8+ T-cell–mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology 136, 1391–1401 (2009).

  106. 106.

    et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 284, 825–829 (1999).

  107. 107.

    et al. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J. Clin. Invest. 116, 3006–3014 (2006).

  108. 108.

    et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 32, 1117–1124 (2000).

  109. 109.

    et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194, 1395–1406 (2001).

  110. 110.

    , , & Conserved hierarchy of helper T cell responses in a chimpanzee during primary and secondary hepatitis C virus infections. J. Immunol. 172, 483–492 (2004).

  111. 111.

    et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58, 974–982 (2009).

  112. 112.

    et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 137, 1289–1300 (2009).

  113. 113.

    , , & Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology 49, 12–21 (2009).

  114. 114.

    , , , & Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection. J. Hepatol. 52, 183–190 (2010).

  115. 115.

    et al. Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines. PLoS Pathog. 6, e1001184 (2010).

  116. 116.

    , , & Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells. J. Virol. 85, 12557–12569 (2011).

  117. 117.

    , , , & Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo. J. Immunol. 131, 1531–1538 (1983).

  118. 118.

    & NK cells controlling virus-specific T cells: rheostats for acute vs. persistent infections. Virology 435, 37–45 (2013).

  119. 119.

    , , & Natural killer cells act as rheostats modulating antiviral T cells. Nature 481, 394–398 (2012).

  120. 120.

    , , , & Absence of mouse 2B4 promotes NK cell–mediated killing of activated CD8+ T cells, leading to prolonged viral persistence and altered pathogenesis. J. Clin. Invest. 120, 1925–1938 (2010).

  121. 121.

    & The depletion of NK cells prevents T cell exhaustion to efficiently control disseminating virus infection. J. Immunol. 190, 641–649 (2013).

  122. 122.

    et al. Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc. Natl. Acad. Sci. USA 109, 1210–1215 (2012).

  123. 123.

    et al. Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells. J. Immunol. 170, 3572–3576 (2003).

  124. 124.

    et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell–mediated deletion. J. Exp. Med. 210, 99–114 (2013).

  125. 125.

    , , & Cytokine-mediated programmed proliferation of virus-specific CD8+ memory T cells. Immunity 38, 131–139 (2013).

  126. 126.

    Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 88, 125–172 (2008).

  127. 127.

    , , & Starring stellate cells in liver immunology. Curr. Opin. Immunol. 20, 68–74 (2008).

  128. 128.

    et al. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand–dependent manners. Gastroenterology 130, 435–452 (2006).

  129. 129.

    et al. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J. Hepatol. 45, 60–71 (2006).

  130. 130.

    et al. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 37, 87–95 (2003).

  131. 131.

    et al. NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner. Lab. Invest. 92, 967–977 (2012).

  132. 132.

    et al. NKp46high expression defines a NK cell subset that is potentially involved in control of HCV replication and modulation of liver fibrosis. Hepatology 56, 1201–1213 (2012).

  133. 133.

    et al. NKp46-mediated killing of human and mouse hepatic stellate cells attenuates liver fibrosis. Gut 61, 885–893 (2012).

  134. 134.

    , & La autoantigen specifically recognizes a predicted stem-loop in hepatitis B virus RNA. J. Virol. 73, 5767–5776 (1999).

  135. 135.

    et al. Platelets mediate cytotoxic T lymphocyte–induced liver damage. Nat. Med. 11, 1167–1169 (2005).

  136. 136.

    et al. Blocking chemokine responsive to γ-2/interferon (IFN)- γ inducible protein and monokine induced by IFN-γ activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus–specific cytotoxic T lymphocytes. J. Exp. Med. 194, 1755–1766 (2001).

  137. 137.

    et al. MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J. Clin. Invest. 113, 1158–1167 (2004).

  138. 138.

    et al. Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus–specific cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 99, 13717–13722 (2002).

  139. 139.

    , , , & Immune pathogenesis of hepatocellular carcinoma. J. Exp. Med. 188, 341–350 (1998).

  140. 140.

    & Hepatitis B virus infection. Lancet 373, 582–592 (2009).

  141. 141.

    & Hepatitis B therapy. Nat. Rev. Gastroenterol. Hepatol. 8, 275–284 (2011).

  142. 142.

    & Future therapies for chronic hepatitis C. Nat. Rev. Gastroenterol. Hepatol. 10, 268–276 (2013).

  143. 143.

    & Extrahepatic manifestations of HCV infection: facts and controversies. J. Hepatol. 31, 369–376 (1999).

  144. 144.

    et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc. Natl. Acad. Sci. USA 87, 6599–6603 (1990).

  145. 145.

    et al. Immune tolerance split between hepatitis B virus precore and core proteins. J. Virol. 79, 3016–3027 (2005).

  146. 146.

    et al. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J. Clin. Invest. 121, 1154–1162 (2011).

  147. 147.

    et al. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology 132, 654–666 (2007).

  148. 148.

    et al. Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection. Hepatology 41, 826–831 (2005).

  149. 149.

    et al. Differential CD4+ and CD8+ T-cell responsiveness in hepatitis C virus infection. Hepatology 33, 267–276 (2001).

  150. 150.

    et al. Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J. Virol. 76, 12423–12434 (2002).

  151. 151.

    et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J. Virol. 83, 9652–9662 (2009).

  152. 152.

    et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J. Virol. 83, 3719–3733 (2009).

  153. 153.

    , , & Genomic analysis of the host response to hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 101, 6669–6674 (2004).

  154. 154.

    et al. Hepatitis B virus–induced lipid alterations contribute to natural killer T cell–dependent protective immunity. Nat. Med. 18, 1060–1068 (2012).

  155. 155.

    et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798–801 (2009).

  156. 156.

    et al. Delayed induction, not impaired recruitment, of specific CD8+ T cells causes the late onset of acute hepatitis C. Gastroenterology 141, 686–695, 695.e1 (2011).

  157. 157.

    et al. The role of virus-specific CD8+ cells in liver damage and viral control during persistent hepatitis B virus infection. J. Exp. Med. 191, 1269–1280 (2000).

  158. 158.

    , & Lymphocyte recruitment to the liver: molecular insights into the pathogenesis of liver injury and hepatitis. Toxicology 254, 136–146 (2008).

  159. 159.

    et al. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J. Immunol. 163, 6236–6243 (1999).

  160. 160.

    et al. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J. Hepatol. 52, 330–339 (2010).

  161. 161.

    et al. Interleukin-12 induction of TH1 cytokines is important for viral clearance in chronic hepatitis B. J. Clin. Invest. 99, 3025–3033 (1997).

  162. 162.

    et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J. Virol. 78, 5707–5719 (2004).

  163. 163.

    et al. Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J. Infect. Dis. 200, 1774–1780 (2009).

  164. 164.

    et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 48, 1440–1450 (2008).

  165. 165.

    et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J. Clin. Invest. 121, 308–317 (2011).

Download references

Acknowledgements

This work was supported by the intramural research program of the National Institute of Diabetes and Digestive and Kidney Diseases, US National Institutes of Health.

Author information

Affiliations

  1. Immunology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, US National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA.

    • Barbara Rehermann

Authors

  1. Search for Barbara Rehermann in:

Competing interests

The author declares no competing financial interests.

Corresponding author

Correspondence to Barbara Rehermann.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nm.3251

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing